严重钙化病变中轨道旋磨与球囊血管成形术在药物洗脱支架植入前的比较(ECLIPSE):一项多中心、开放标签、随机试验
ECLIPSE试验在美国104个中心随机分配2005例严重钙化冠脉病变患者,比较药物洗脱支架植入前轨道旋磨(1008例,1250处病变)与球囊血管成形术(997例,1242处病变)。主要终点之一1年靶血管失败率在轨道旋磨组为11.5%(95%CI 9.7-13.7),球囊组为10.0%(8.3-12.1),绝对差1.5%(96%CI -1.4至4.4),HR 1.16(96%CI 0.87-1.54),p=0.28。光学相干断层扫描亚组中最大钙化处最小支架面积分别为7.67 mm²(SD 2.27)与7.42 mm²(SD 2.54),平均差0.26(99%CI -0.31至0.82),p=0.078。作者结论认为这些数据支持对多数可被导丝通过并扩张的钙化冠脉病变采用球囊优先策略,并在血管内影像指导下进行。
要点
- 在术者判断适合两种策略的严重钙化病变中,支架前轨道旋磨组1年靶血管失败11.5%(95%CI 9.7-13.7),球囊组10.0%(8.3-12.1),HR 1.16(96%CI 0.87-1.54),p=0.28,无显著差异。
- 光学相干断层扫描亚组最大钙化处最小支架面积轨道旋磨组7.67 mm²(SD 2.27) vs 球囊组7.42 mm²(SD 2.54),平均差0.26(99%CI -0.31至0.82),p=0.078。
- 1年内心脏性死亡轨道旋磨组39/1008例,球囊组26/997例。
- 作者结论支持对多数可被导丝通过并扩张的钙化冠脉病变采用球囊优先策略,并在血管内影像指导下进行。
适用人群与场景
- 美国104个中心、年龄≥18岁、严重钙化冠脉病变且术者判断随机分配病变适合轨道旋磨与球囊两种策略的患者,随机1:1分组。
诊断标准与关键阈值
- 严重钙化由核心实验室血管造影确认:轨道旋磨组1120处病变中1088处(97.1%),球囊组1101处病变中1068处(97.0%)。
- 随机分配病变需术者判断为适合轨道旋磨与球囊两种治疗策略。
处置流程与药物剂量
- 随机分配至轨道旋磨或球囊血管成形术后,行药物洗脱支架PCI。
- PCI由血管内影像指导:轨道旋磨组627/1008例(62.2%),球囊组619/997例(62.1%)。
研究设计与关键结果
- 多中心、开放标签、随机对照试验,2005例患者2492处病变随机分配至轨道旋磨(1008例,1250处病变)或球囊血管成形术(997例,1242处病变)后行药物洗脱支架植入;中位年龄70.0岁(IQR 64.0-76.0),女性541/2005例(27.0%),男性1464/2005例(73.0%)。
- 共同主要终点1年靶血管失败(心脏性死亡、靶血管心肌梗死或缺血驱动的靶血管血运重建复合终点):轨道旋磨组113/1008例(11.5%,95%CI 9.7-13.7) vs 球囊组97/997例(10.0%,95%CI 8.3-12.1),绝对差1.5%(96%CI -1.4至4.4),HR 1.16(96%CI 0.87-1.54),p=0.28。
- 共同主要终点光学相干断层扫描亚组最大钙化处最小支架面积:轨道旋磨组276例患者286处病变,均值7.67 mm²(SD 2.27) vs 球囊组279例患者292处病变,均值7.42 mm²(SD 2.54),平均差0.26(99%CI -0.31至0.82),p=0.078。
- 1年内心脏性死亡:轨道旋磨组39/1008例,球囊组26/997例。
证据类型、等级与局限
- 证据类型:多中心、开放标签、随机对照试验(ECLIPSE),注册号NCT03108456,2年随访进行中。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论认为,在术者判断适合两种策略的严重钙化病变中,常规支架前轨道旋磨与球囊策略相比未增加最小支架面积或降低1年靶血管失败率。
- 作者结论支持对多数可被导丝通过并扩张的钙化冠脉病变采用球囊优先策略,并在血管内影像指导下进行。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Coronary artery calcification is common among patients undergoing percutaneous coronary intervention (PCI), and severe coronary artery lesion calcification is associated with increased procedural complexity, stent under-expansion, and high rates of intraprocedural complications and out-of-hospital adverse events. Whether calcium ablation before stent implantation can mitigate these adverse events is not currently established. We aimed to prospectively compare orbital atherectomy with a balloon angioplasty-based strategy before stent implantation for the treatment of severely calcified coronary lesions.
METHODS: In this multicentre, open-label, randomised controlled trial conducted at 104 medical centres in the USA, patients (aged ≥18 years) with severely calcified coronary lesions were randomly assigned (1:1) to orbital atherectomy or balloon angioplasty before PCI with drug-eluting stents using a web-based system (block sizes of four and six) and stratified by intended treatment of single versus multiple lesions and enrolling site. Randomly assigned lesions were deemed by operators to be eligible for both treatment strategies. Operators and patients were not masked to treatment. The two powered coprimary study endpoints were target vessel failure at 1 year (a composite of cardiac death, target vessel myocardial infarction, or ischaemia-driven target vessel revascularisation) and post-procedural minimal stent area at the site of maximal calcification, as assessed by intravascular optical coherence tomography in an imaging patient cohort. Primary analyses were by intention-to-treat. The trial is registered at ClinicalTrials.govNCT03108456, and 2-year follow-up is ongoing.
FINDINGS: From March 27, 2017, to April 13, 2023, 2005 patients with 2492 lesions were randomly assigned to lesion preparation with orbital atherectomy (1008 patients with 1250 lesions) or balloon angioplasty (997 with 1242 lesions) before stent implantation. Median patient age was 70·0 years (IQR 64·0-76·0). 541 (27·0%) of 2005 patients were female and 1464 (73·0%) were male. Angiographically severe calcium was confirmed by the core laboratory in 1088 (97·1%) of 1120 lesions assigned to orbital atherectomy and 1068 (97·0%) of 1101 lesions assigned to balloon angioplasty. PCI was guided by intravascular imaging in 627 (62·2%) of 1008 patients in the orbital atherectomy group and 619 (62·1%) of 997 in the balloon angioplasty group. Target vessel failure events within 1 year occurred in 113 of 1008 patients in the orbital atherectomy group (1-year target vessel failure 11·5% [95% CI 9·7 to 13·7]) and in 97 of 997 patients in the balloon angioplasty group (10·0% [8·3 to 12·1]; absolute difference 1·5% [96% CI -1·4 to 4·4]; hazard ratio 1·16 [96% CI 0·87 to 1·54], p=0·28). Among those in the optical coherence tomography substudy cohort (276 patients with 286 lesions in the orbital atherectomy group and 279 patients with 292 lesions in the balloon angioplasty group), the mean minimal stent area at the site of maximal calcification was 7·67 mm2 (SD 2·27) in the orbital atherectomy group and 7·42 mm2 (2·54) in the balloon angioplasty group (mean difference 0·26 [99% CI -0·31 to 0·82]; p=0·078). Cardiac death events within 1 year occurred in 39 of 1008 patients in the orbital atherectomy group and in 26 of 997 in the balloon angioplasty group.
INTERPRETATION: Routine treatment with orbital atherectomy before drug-eluting stent implantation did not increase minimal stent area or reduce the rate of target vessel failure at 1 year compared with a balloon angioplasty-based approach in severely calcified lesions deemed eligible for both treatment strategies. These data support a balloon-first approach for most calcified coronary artery lesions that can be crossed and dilated before stent implantation, guided by intravascular imaging.
FUNDING: Abbott Vascular (Abbott).
参考来源
- Kirtane AJ, Généreux P, Lewis B, et al. Orbital atherectomy versus balloon angioplasty before drug-eluting stent implantation in severely calcified lesions eligible for both treatment strategies (ECLIPSE): a multicentre, open-label, randomised trial. Lancet. 2025. PMID: 40174596. doi:10.1016/S0140-6736(25)00450-7
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。